Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

• DOI: 10.1007/s11523-020-00720-2
• Publication Date: 2020-06-04T20:02:58Z
• Authors: Simon Chowdhury; Anders Bjartell; Nicolaas Lumen; Pablo Maroto; Thomas Paiss; Francisco Gomez-V...; Alison Birtle; Gero Kramer; Ewa Kalinka; Dominique Spaëth; Susan Feyerabend; Vsevolod Matveev; Florence Lefresne; Martin Lukac; Robert Wapenaar; Luis Costa
• Keywords: Enzalutamide; Abiraterone acetate

Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is need to improve the clinical understanding and treatment of this disease, particularly in real-world setting among patients who are under-represented trials. We aimed evaluate characteristics outcomes received their first for metastatic castration-resistant (mCRPC) routine practice, independent used, including subgroups with baseline cardiac diabetes mellitus, or visceral metastases. Prospective, noninterventional analysis patient record data multicenter Prostate Cancer Registry (PCR) men mCRPC. The were collected 16 countries aim recruiting more than 3000 between 2013 2016. study end date was 9 July 2018. Data evaluated included characteristics, exposure, efficacy [overall (OS) time progression (TTP)] treated abiraterone acetate plus prednisone prednisolone (collectively, “abiraterone”), enzalutamide, docetaxel. Descriptive reported from overall population cardiovascular effects compared population. enrollment period lasted 2.5 years, each followed maximum 3 years. A total 1874 PCR had not previous mCRPC at baseline, although they androgen-deprivation therapy. Prevalent co-morbidities disease 65.4% mellitus 17.4% patients. Baseline suggested that advanced docetaxel treatment. In population, median abiraterone, as first-line therapy 9.6, 10.3, 7.6 months, respectively, OS 27.1, 27.9 respectively. Outcomes similar those whole analysis. As expected, metastases shorter TTP This shows, time, effectiveness parallel mCRPC, such These findings provide meaningful information help manage studies. ClinicalTrials.gov identifier NCT02236637; registered September 2014.